Relay Therapeutics logo
Relay Therapeutics
RLAY | NASDAQ
Chart Builder DCF Calculator
$17.27
-$0.82 (-4.53%)
At close: Nov 16, 2026, 4:00 PM ET
$17.50
+$0.23 (+1.33%)
After-hours: Nov 16, 2026, 7:30 PM ET

Relay Therapeutics Company Profile

Company profile explained

Company Profile

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

Key Executives

Name Position
Sanjiv K. Patel MBBS Chief Executive Officer, President & Director
Thomas Catinazzo Chief Financial Officer
David Elliot Shaw Founder
Donald A. Bergstrom President of Research & Development
Dorothee Kern Founder
Jim Watters Chief Scientific Officer
Mahesh Padval Chief Pharmaceutical Development Officer
Mark Murcko Founder & Independent Director
Matthew Jacobson Founder
Peter Rahmer Chief Corporate Development Officer
Soo-Yeun Lim Senior Vice President & General Counsel

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 08, 2026 4 Filing
Oct 08, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 28, 2026 4 Filing
View All SEC Filings ➞
Relay Therapeutics
Relay Therapeutics logo
Country United States
IPO Date Jul 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 202
CEO Sanjiv K. Patel

Contact Details

60 Hampshire Street Cambridge, Massachusetts 02139 United States

Stock Details

Ticker Symbol RLAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001812364
CUSIP Number 75943R102
ISIN Number US75943R1023
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.